Evidence map›Paper›PMID 26310973›Full record

ArticleMolecular neurobiology2016

The Effect of Melatonin on Behavioral, Molecular, and Histopathological Changes in Cuprizone Model of Demyelination.

Gelareh Vakilzadeh, Fariba Khodagholi, Tahereh Ghadiri, Amir Ghaemi, Farshid Noorbakhsh, Mohammad Sharifzadeh, Ali Gorji

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Melatonin and vitamin D, two sides of the same coin, better to land on its edge to improve multiple sclerosis.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Gelareh VakilzadehShefa Neuroscience Research Center, Khatam-Alanbia Hospital, Tehran, Iran.
Fariba KhodagholiNeuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Tahereh GhadiriShefa Neuroscience Research Center, Khatam-Alanbia Hospital, Tehran, Iran.
Amir GhaemiInfectious Diseases Research Center, Department of Microbiology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
Farshid NoorbakhshDepartment of Immunology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad SharifzadehDepartment of Neuroscience, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. msharifzadeh@sina.tums.ac.ir.
Ali GorjiShefa Neuroscience Research Center, Khatam-Alanbia Hospital, Tehran, Iran. gorjial@uni-muenster.de.
Khatam University · IRTehran University of Medical Sciences · IRGolestan University · IRShahid Beheshti University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central nervous system. The protective effects of melatonin (MLT) on various neurodegenerative diseases, including MS, have been suggested. In the present study, we examined the effect of MLT on demyelination, apoptosis, inflammation, and behavioral dysfunctions in the cuprizone toxic model of demyelination. C57BL/6J mice were fed a chaw containing 0.2 % cuprizone for 5 weeks and received two doses of MLT (50 and 100 mg/kg) intraperitoneally for the last 7 days of cuprizone diet. Administration of MLT improved motor behavior deficits induced by cuprizone diet. MLT dose-dependently decreased the mean number of apoptotic cells via decreasing caspase-3 and Bax as well as increasing Bcl-2 levels. In addition, MLT significantly enhanced nuclear factor-κB activation and decreased heme oxygenase-1 level. However, MLT had no effect on interleukin-6 and myelin protein production. Our data revealed that MLT improved neurological deficits and enhanced cell survival but was not able to initiate myelin production in the cuprizone model of demyelination. These findings may be important for the design of potential MLT therapy in demyelinating disorders, such as MS.

Indexed as

Disease Models, AnimalAnimalsAntioxidantsCuprizoneDemyelinating DiseasesDose-Response Relationship, DrugInflammation MediatorsInjections, IntraperitonealMaleMelatoninMiceMice, Inbred C57BLPain MeasurementRandom AllocationAntioxidantsCuprizoneInflammation MediatorsMelatoninCell deathCorpus callosumNeuroinflammationPineal glandRemyelination

Identifiers

PMID26310973
OpenAlexW1194272897

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.